# TQB2450

Source: https://onco.cc/drugs/tqb2450/  
OnCo record `tqb2450` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

TQB2450 is an experimental monoclonal antibody from Chia Tai Tianqing Pharmaceutical in phase 3 trials for renal cell carcinoma and non-small-cell lung cancer, aimed at PD-L1 and PD-1.

## Summary

TQB2450 is a monoclonal antibody developed by Chia Tai Tianqing Pharmaceutical. Its targets are PD-L1 and PD-1 (the sponsor names PD-L1). The sponsor states: TQB2450 is a humanised monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents PD-L1 binding to PD-1 and B7.1 receptors on T cells, restoring T-cell activity and enhancing immune response. ClinicalTrials.gov describes the intervention as: TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents PD-L1 from binding to PD-1 and B7.1 receptors on T cell surface, restores T cell activity, thus enhancing immune response and has potenti. It is the investigational product in 2 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, including the phase 3 study NCT04523272 (A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule Versus Sunitinib in Subjects With Advanced Renal Cancer), in renal cell carcinoma and non-small-cell lung cancer. The largest, NCT04523272, plans to enrol 528 participants (actual) with primary completion was scheduled for 2025-06 on the registry. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.

## Fields

- Kind: Treatment
- Status: phase-3
- Last checked: 2026-09-11
- Tags: pipeline; ctgov-ingest
- Modality: monoclonal antibody
- Mechanism: TQB2450 is a humanised monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents PD-L1 binding to PD-1 and B7.1 receptors on T cells, restoring T-cell activity and enhancing immune response.

## Sources

- ClinicalTrials.gov: trials of TQB2450: https://clinicaltrials.gov/search?intr=TQB2450

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Renal cell carcinoma](https://onco.cc/cancers/rcc/)
- targets: [CD80 (B7-1)](https://onco.cc/targets/cd80/), [PD-1](https://onco.cc/targets/pd1/), [PD-L1](https://onco.cc/targets/pdl1/)
- companies: [Sino Biopharmaceutical (Chia Tai Tianqing)](https://onco.cc/companies/sino-biopharm/)
- trials: [A Clinical Study of TQB2450 Injection Combined With Chemotherapy or Anlotinib Hydrochloride Capsule in the Treatment of Non Small Cell Lung Cancer](https://onco.cc/trials/nct05913089/), [A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule Versus Sunitinib in Subjects With Advanced Renal Cancer](https://onco.cc/trials/nct04523272/)

---
JSON: https://onco.cc/api/v1/entities/tqb2450.json